$BAYN (+1.36%)

Bayer shares currently have a mixed outlook. Following the Monsanto takeover, the company continues to be under pressure from legal disputes, particularly in the USA due to glyphosate lawsuits, which are causing high costs. The share has been under pressure since then and has struggled to recover. On the positive side, Bayer is well positioned in pharmaceuticals and crop science and is pursuing key research areas such as cancer therapies. However, profits are uncertain and volatile. In the long term, Bayer could benefit from innovations, but the risk remains high until the legal disputes are resolved.